Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Key facts

Sponsor

Vanderbilt-Ingram Cancer Center

Principal Investigator

Laura Goff, MD

Vanderbilt-Ingram Cancer Center

Intervention

erlotinib hydrochloride(drug)

Enrollment

28 enrolled

Eligibility

18 years · All sexes

Timeline

2009 – 2016

Study locations (1)

• Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07265674
  A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
  J-Pharma Co., Ltd.
• RECRUITINGPHASE3NCT06282575
  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
  Jazz Pharmaceuticals
• RECRUITINGNCT07007832
  Bile Omics for Diagnosing Indeterminate Biliary Strictures
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• ACTIVE NOT RECRUITINGPHASE1NCT03257761
  Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
  University of Southern California

See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract →